Table 1.
Clinical and demographic data for 91 patients constituting our first 100 awake surgeries
| (Parameter/Variable) | Value/Number (%) |
|---|---|
| Age (years), n = 91 | |
| Mean | 49.2 |
| Range | 19–74 |
| Sex (n = 91) | |
| Male | 48 |
| Female | 43 |
| Symptoms at presentation (n = 91) | |
| Seizure/collapse | 49 |
| Headache/nausea/confusion | 6 |
| Neurology | 25 |
| Incidental finding | 2 |
| Surveillance | 8 |
| Unknown | 1 |
| Hemisphere of surgery (n = 100) | |
| Left | 66 |
| Right | 34 |
| Type of surgery (n = 100) | |
| First operation | 79 |
| First awake surgery (re-do operation) | 12 |
| Repeat awake surgery | 9 |
| Radiological tumor resection (n = 100) | |
| Gross total | 40 |
| Near total (> 90% resection) | 28 |
| Subtotal (< 90%) | 32 |
| WHO tumor grade (n = 100) | |
| II | 20 |
| Oligodendroglioma | 11 |
| Astrocytoma | 9 |
| III | 27 |
| Oligodendroglioma | 8 |
| Astrocytoma | 18 |
| Clear cell ependymoma | 1 |
| IV | 51 |
| Metastasis | 2 |
| IDH status | |
| IDH+ | 43 |
| IDH− | 43 |
| IDH unavailable | 5 |
IDH-mutated tumors (denoted as “IDH + ”) included the common IDH1R132H mutation as well as rarer IDH1 and IDH2 variants
WHO World Health Organization, IDH Isocitrate dehydrogenase